Sequiris invest £40m into expansion of Liverpool plant creating 100 new jobs

pharmafile | October 11, 2018 | News story | Manufacturing and Production, Research and Development |  Jobs, Vaccine, investment, liverpool 

The Liverpool-based vaccine-maker Sequiris is investing £40 million into the expansion of its operations in the Speke area of Liverpool.

The multi-million pound investment is set to create 100 new jobs while allowing vaccines to be created more quickly in preparation for outbreaks of the flu. While vaccines are currently shipped to Italy for packaging, the expansion will now allow the process of packing the vaccines into syringes and capsules to be done in the UK.

The company, which is as of now the second biggest influenza vaccine company in the world, provides around half of the vaccines used in the UK. The project which is expected to be complete in 2019 will increase the safety of the government contracted vaccine makers products.

Advertisement

The investment will also increase the speed with which vaccines reach the market in the UK.

Dr Laura O’Brien, vice president of operations and site head at Liverpool, commented: “This investment means we can complete production of more pandemic vaccine much more rapidly, saving vital days in getting vaccines out to protect the British population as well as to other countries around the world.”

Louis Goss

Related Content

Tridem begins phase Ib trial of Parkinson’s disease vaccine

Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

ESTEVE CDMO adds $17.5m to Illinois expansion

ESTEVE CDMO is investing a further $17.5m to expand capacity and containment capabilities at its …

Liverpool launches £20m lab for infectious disease drug discovery

A new £20m high-security laboratory using robotics, artificial intelligence (AI) and human organoids to accelerate …

The Gateway to Local Adoption Series

Latest content